@article{3079687,
    title = "A new mononuclear cell (MNC) RNase h activity-based parameter (ψ with possible prognostic value in assessing progression in acute myeloid leukaemia",
    author = "Papaphilis, A.D. and Kamper, E.F. and Grammenou, S. and Kattamiss, C. and Pangalis, G.A.",
    journal = "Clinical Lymphoma Myeloma and Leukemia",
    year = "1990",
    volume = "1",
    number = "3-4",
    pages = "209-220",
    publisher = "Informa Healthcare",
    doi = "10.3109/10428199009042482",
    keywords = "ribonuclease, acute granulocytic leukemia;  article;  clinical article;  female;  human;  male;  mononuclear cell;  parameter;  prognosis;  survival",
    abstract = "A new biological parameter (ψ has been obtained and proposed here to serve in the assessment of acute myeloid leukemia (AML) progression. It is a function of the activity of RNase H (EC 3.1.4.34), the latter determined in mononuclear cells from the peripheral blood of AML patients. Using a series of patients at the time of diagnosis and after 1-2 cycles of chemotherapy, the enzyme was assayed before the several times during chemotherapy. The derivation of 4 was based on evidence suggesting that the enzyme level correlates with the proliferating leukaemic blasts and their progenitors. Values ψgt;1 signify the presence of clonogenic leukaemic progenitor cells in the peripheral circulation. When these high (> 1) ψ values were found during chemotherapy, in these cases it was possible to predict an increase of the peripheral blast pool, with 82% success, occurring 5-35 days before cytologic relapse. In the patients in whom at some stage during treatment, ψ acquired values above unity or in whom ψ increased progressively, survival time was in linear correlation with the time period from the initiation of treatment to the documentation of this high ψ estimate. These results suggest that a patient's relapse risk can be defined by ψ with some degree of precision. © 1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted."
}